Skip to main content

Intentional Self-Harm Following Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) Use in Patients with Obesity: A Descriptive Analysis

Basic Details
Date Posted
Status
In progress
Medical Product
glucagon-like peptide-1 (GLP-1) receptor agonists
Health Outcome(s)
intentional self-harm
Description

In this request, we identified cohorts of individuals with an obesity diagnosis overall and with use of glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) or other weight loss agents in the Sentinel Distributed Database (SDD) and estimated the rates of intentional self-harm.

The study period includes data from October 1, 2015 to September 30, 2023. We distributed this request to 14 Sentinel Data Partners on March 18, 2024.

The analytic packages associated with this analysis can be found externally in Sentinel's Git Repository located here. The Git Repository serves as Sentinel's version control tracking system for analytic packages and technical documentation.

Deliverables (1)
Sentinel Analytic Package: Intentional Self-Harm Following Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) Use in Patients with Obesity: A Descriptive Analysis
Additional Details
FDA Center
CDER
Time Period
October 1, 2015 - September 30, 2023
Analysis Type
Descriptive
Population / Cohort
Individuals aged 18 and older
Data Sources
Sentinel Distributed Database (SDD)
Related Links
Sentinel Drug Study: Glucagon-Like Peptide-1 Receptor Agonists & Intentional Self-Harm
Intentional Self-Harm Algorithm Defined in "Intentional Self-Harm Following Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Use in Patients with Obesity: A Descriptive Analysis"
Sentinel Drug Analysis: Intentional Self-Harm Following Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) Use in Patients with Diabetes: An Inverse Probability of Treatment Weighting Analysis